Natco Pharma Quarterly Results
Natco Pharma quarterly results. In Sept 2026, Natco Pharma (NATCOPHARM) reported revenue ₹1,019 Cr and net profit ₹203 Cr — revenue -30.3% YoY. Also explore Natco Pharma share price performance to track price trends across different timeframes.
NATCOPHARM Quarterly Results — Revenue, Profit & EPS Highlights
Natco Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View NATCOPHARM yearly price range for the annual high/low range and current price position.
- Revenue of ₹1,019 Cr in Sept 2026 (+24.7% vs Mar 2026, -30.3% vs Sept 2025)
- Net Profit of ₹203 Cr in Sept 2026 (-24.5% vs Mar 2026, -60.8% vs Sept 2025)
- EBITDA of ₹310 Cr in Sept 2026 (+51.2% vs Mar 2026)
- Operating Margin of 27.0% in Sept 2026 (+10.0pp vs Mar 2026)
- Earnings Per Share of ₹11.31 in Sept 2026 (-24.4% vs Mar 2026)
Natco Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
NATCOPHARM quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2026 | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1,019 | 817 | 794 | 1,463 | 1,287 | 24.7% | -30.3% |
| Net Profit (₹ Cr) | 203 | 269 | 207 | 518 | 406 | - | - |
| EBITDA (₹ Cr) | 310 | 205 | 246 | 679 | 614 | - | - |
| EPS (₹) | 11.31 | 14.96 | 11.53 | 28.94 | 22.70 | - | - |
| Operating Margin (%) | 27.0% | 17.0% | 25.0% | 42.0% | 45.0% | - | - |
NATCOPHARM Share Price Trend — 1-Year Movement Across Quarterly Results
Natco Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Natco Pharma screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
NATCOPHARM vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Natco Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2026 |
₹451,074.97 Cr | 1900.0 | 16,617 | 1,995 | +10.6% | - | 12.0% | 228.9 |
|
Divis Laboratories
Sept 2026 |
₹294,139.19 Cr | 11178.0 | 3,770 | 1,127 | +26.3% | - | 29.9% | 263.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4611.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 400.6 |
|
Apollo Hospitals
Sept 2026 |
₹126,832.45 Cr | 8738.0 | 7,673 | 660 | +15.2% | - | 8.6% | 199.4 |
|
Laurus Labs
Sept 2026 |
₹125,946.78 Cr | 2306.0 | 2,219 | 436 | +21.7% | - | 19.6% | 282.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores